IL1B and systemic-onset juvenile idiopathic arthritis: This has led to the novel application of drugs that target IL-1β (for example, anakinra, canakinumab and rilonacept) in conditions such as periodic fever syndromes, Still’s disease, Schnitzler’s syndrome, and gouty arthritis where conventional anti-inflammatory drugs fail to provide long-lasting relief [35].